Bipolarity studies

This extension study evaluates the long-term safety and tolerability of KarXT for mania or mania with mixed features in people living with bipolarity type I.

Researchers compare KarXT with placebo, each added to lithium, valproate or lamotrigine, in people with bipolarity type I experiencing mania, with or without mixed features. They want to know whether adding KarXT improves manic symptoms and assess its safety.

Researchers compare KarXT with placebo to find out whether it reduces manic symptoms in people with bipolarity type I. They also assess side effects and safety during treatment.

Researchers compare KarXT with placebo during a three-week hospital treatment period for people with bipolarity type I experiencing mania, with or without mixed features. They assess changes in manic symptoms and monitor safety.

Researchers compare NBI-1117568 with placebo to find out whether it reduces manic symptoms in adults with bipolarity type I who are experiencing mania, with or without mixed features. They also assess safety and how the medicine behaves in the body.

Researchers are testing whether a study of blue-light-blocking glasses is practical and acceptable for adults hospitalized with mania and bipolarity type I. Participants wear the glasses while researchers assess manic symptoms, sleep and how well the study procedures work.

Researchers compare two doses of icalcaprant with placebo to find out whether the medicine improves depression symptoms in adults with bipolarity type I or II. Participants take capsules for six weeks while researchers also monitor side effects.

Researchers follow young people with bipolarity or related mood conditions to understand how symptoms, inflammation and treatment relate to recovery and new mood episodes. Families complete interviews and questionnaires, while researchers track care over time.

Researchers compare brenipatide with placebo, both added to usual treatment, to find out whether it delays a new mood episode in adults with bipolarity. They monitor changes in symptoms and the safety of the added medicine.

Researchers compare overnight melatonin-related urine measurements in people with bipolarity type I who respond well or poorly to lithium, while their mood is stable. They want to understand whether body-clock biology helps explain differences in lithium response; melatonin is being measured, not given as treatment.

Researchers study whether patterns of appetite and metabolism can guide the choice of weight-loss medicines for adults with obesity and bipolarity. Participants receive a medicine selected for their obesity profile, while researchers assess the approach’s feasibility and effects.

Researchers compare blue-light-blocking glasses with clear glasses in adults hospitalized for mania linked to bipolarity. Both groups continue usual medication, and researchers assess whether filtering blue light changes manic symptoms and sleep.